Institutions / Defilade Capital Management, L.P.

Defilade Capital Management, L.P.

CIK 2088557 · Institution · as of Dec 31, 2025
Portfolio value
$737.73M
Positions
33
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 33 →
CompanyClassValueShares% of portfolio
Pfizer Inc$54.87M2,203,5047.4%
AbbVie Inc.$52.02M227,6697.1%
Novartis AG$50.02M362,8166.8%
Icu Medical INC/DE$48.61M340,7456.6%
PACS Group, Inc.$43.98M1,145,4856.0%
ELI LILLY & Co$34.34M31,9504.7%
STERIS plc$34.30M135,3074.6%
Olema Pharmaceuticals, Inc.$30.87M1,234,6344.2%
Revolution Medicines, Inc.$28.95M363,4543.9%
Biogen Inc.$28.51M161,9923.9%
Nuvalent, Inc.$27.06M269,0433.7%
Intuitive Surgical Inc$25.86M45,6623.5%
Henry Schein Inc$24.22M320,4223.3%
Globus Medical Inc$23.33M267,2123.2%
Xencor Inc$21.66M1,414,7552.9%
Cogent Biosciences, Inc.$20.20M568,6192.7%
Align Technology, Inc.$20.00M128,0602.7%
Ascendis Pharma A/S$18.27M85,6942.5%
Dexcom Inc$16.25M244,8812.2%
Becton Dickinson & Co$15.76M81,2072.1%
AtriCure Inc$15.73M397,6362.1%
LivaNova PLC$14.85M241,4132.0%
Alphatec Holdings, Inc.ATECCommon Stock$13.19M626,7541.8%
Denali Therapeutics Inc.$10.84M656,7131.5%
Glaukos Corp$10.35M91,7031.4%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.